RG6648 / Roche, MediLink - LARVOL DELTA

A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=155 | Recruiting | Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=155 | Not yet recruiting | Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor

Preclinical development of a next generation antibody drug conjugate (ADC) targeting cMET for treatment of solid tumors (AACR 2024) - "These non-clinical data suggest the stability of the linker in circulation as well as efficient release of the payload in tumors with improved therapeutic window. Taken together, preclinical data suggest that YL211 could be a promising treatment strategy for cMET positive cancer patients."

Preclinical • Oncology • Solid Tumor • CASP7

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation antibody drug conjugate in Oncology (PRNewswire) - "MediLink Therapeutics...announced today that it has entered into a worldwide collaboration and license agreement with Roche...on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors....Under the terms of the agreement, MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of MediLink's ADC asset, YL211. MediLink will work together with Roche's R&D unit China Innovation Center of Roche (CICoR) to initiate the Phase I clinical trial of YL211 and Roche will then take over the further development and commercialization globally. MediLink will receive upfront and near-term milestone payments totaling $50 million and, together with additional development, regulatory and commercial milestone payments potentially reaching a total deal value nearing $1 billion, as well as tiered royalties on future global annual net sales."

Licensing / partnership • Oncology